A multi-omic brain gut microbiome signature differs between IBS subjects with different bowel habits [PDF]
Alterations of the brain-gut-microbiome system (BGM) have been implicated in the pathophysiology of irritable bowel syndrome (IBS), yet bowel habit-specific alterations have not been elucidated.
Lisa A. Kilpatrick +27 more
core +1 more source
Background and Aims. Although the differential expression of microRNA (miRNA) genes has been identified in many diseases, little information exists concerning the miRNA expression profile in type 2 diabetes mellitus (T2DM) with diarrhea-predominant ...
Wenhua Tao +5 more
doaj +1 more source
Oral and fecal microbiota in patients with diarrheal irritable bowel syndrome
Background: This study aimed at investigating the characteristics and correlation between oral (tongue coating) and fecal microbiota in patients with diarrheal irritable bowel syndrome (IBS-D).
Binbin Tang +5 more
doaj +1 more source
Two new choices for patients with IBS-D [PDF]
Eluxadoline (Viberzi—Patheon), a novel medication, and rifaximin (Xifaxan—Salix), a previously approved agent, have received FDA approval for the treatment of adult patients with irritable bowel syndrome with diarrhea (IBS-D). The condition affects an estimated 15 million patients in the United States, with women twice as likely as men to have IBS-D.
openaire +1 more source
Gut microbiome signatures reflect different subtypes of irritable bowel syndrome
Irritable bowel syndrome (IBS) is a heterogeneous condition with multifactorial pathogenesis. We studied deeply phenotyped individuals with microbiota sequencing enrolled in the American Gut Project.
Qi Su +6 more
doaj +1 more source
Research Status and Thoughts on the Comparative Effect of Traditional Chinese Medicine in the Treatment of IBS-D [PDF]
Diarrhea irritable bowel syndrome (IBS-D) is a common clinical disease with high prevalence and recurrent episodes. Patients with IBS-D often suffer from anxiety and depression, which bring a huge medical burden to the society.
Min CHEN, Xin XIE, Yunzhou SHI, Hui ZHENG, Qiaofeng WU, Haiyan ZHOU, Zhigang LI, Shuguang YU
core +2 more sources
Contemporary management of pain in cirrhosis: Toward precision therapy for pain
Abstract Chronic pain is highly prevalent in patients with cirrhosis and is associated with poor health‐related quality of life and poor functional status. However, there is limited guidance on appropriate pain management in this population, and pharmacologic treatment can be harmful, leading to adverse outcomes, such as gastrointestinal bleeding ...
Alexis Holman +4 more
wiley +1 more source
Serum zonulin is elevated in IBS and correlates with stool frequency in IBS‐D [PDF]
Background Studies have shown increased intestinal permeability in irritable bowel syndrome. Validating serum biomarkers for altered intestinal permeability in irritable bowel syndrome will facilitate research and pathophysiology‐based therapy. Objective
Prashant Singh +9 more
openaire +2 more sources
Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C : a pilot study [PDF]
Aims Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder, associated with alterations of bowel function, abdominal pain and other symptoms related to the GI tract. Recently the endogenous cannabinoid system (ECS) was shown to
Wood, JodiAnne +44 more
core +2 more sources
Tryptase and Protease-Activated Receptor 2 Expression Levels in Irritable Bowel Syndrome
Background/AimsPrevious studies have revealed that mast cells (MCs) may activate the protease-activated receptors and release of neuropeptides involved in the pathogenesis of irritable bowel syndrome (IBS).
doaj +1 more source

